A Pediatric Phase 1 Trial and Pharmacokinetic Study of Ispinesib: A Children's Oncology Group Phase I Consortium Study

PURPOSE: To determine the maximum-tolerated dose, dose-limiting toxicities and pharmacokinetics of the kinesin spindle protein inhibitor ispinesib in pediatric patients with recurrent or refractory solid tumors. SUBJECTS AND METHODS: Ispinesib was administered as 1-hour intravenous infusion weekly ×...

詳細記述

保存先:
書誌詳細
主要な著者: Souid, Abdul-Kader, Dubowy, Ronald L., Ingle, Ashish M., Conlan, Maureen G., Sun, Junfeng, Blaney, Susan M., Adamson, Peter C.
フォーマット: Artigo
言語:Inglês
出版事項: 2010
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3053384/
https://ncbi.nlm.nih.gov/pubmed/20712019
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.22609
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料